INCY - Incyte Corporation
Cetera Investment Advisers trimmed its position in Incyte Corporation (NASDAQ: INCY) by 18.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,490 shares of the biopharmaceutical company's stock after selling 5,879 shares during the period. Cetera Investment Advisers' holdings in
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value investors?
Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis.
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte NASDAQ: INCY reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA.
Incyte Corporation ends the first half of 2026 on a high note. Yesterday, its stock reached a 52-week high of $120.70. In my view, key drivers behind Incyte's recent rally are the promising efficacy of latarcibart in von Willebrand disease, along with strong performance from Opzelura and Zynyz.
Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago.
Drugmaker Incyte Corp reported on Tuesday higher second-quarter earnings and raised its annual revenue forecast after it settled a lawsuit with the U.S. government over Medicaid rebates tied to eczema cream Opzelura.
On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, picked ServiceNow, Inc. (NYSE:NOW).
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates.
Entropy Technologies LP increased its position in Incyte Corporation (NASDAQ: INCY) by 29.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 26,077 shares of the biopharmaceutical company's stock after buying an additional 5,961 shares during the period. Entropy Technologies LP's holdings in Incyte were
Dai ichi Life Insurance Company Ltd boosted its holdings in Incyte Corporation (NASDAQ: INCY) by 60.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,971 shares of the biopharmaceutical company's stock after acquiring an additional 6,008 shares during the quarter. Dai
INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.